NuCana reports Q2 EPS GBP 0.12 vs.GBP 0.10 last year

Reports as of June 30 NuCana had cash and cash equivalents of GBP 11.6M compared to GBP 12.9M as of March 31 and GBP 17.2M at December 31. NuCana continues to advance its numerous clinical programs and reported a net loss of GBP 7M for the quarter ended June 30 as compared to a net loss of GBP 5.4M for the quarter ended June 30, 2023. Basic and diluted loss per ordinary share was GBP 0.12 for the quarter ended June 30 as compared to GBP 0.10 per ordinary share for the comparable quarter ended June 30, 2023.”During the first half of the year, we remained focused on the execution of our clinical programs, all of which are on track for data updates this year,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “NUC-3373, a ProTide transformation of 5-FU, is currently being evaluated in three clinical studies: NuTide:323, a randomized, 182-patient Phase 2 study for the second-line treatment of patients with metastatic colorectal cancer; NuTide:302, a Phase 1/2 study in patients with metastatic colorectal cancer; and NuTide:303, a Phase 1b/2 study in patients with solid tumors and lung cancer. We are pleased to report that all three studies are progressing as planned, and we look forward to sharing data updates in the second half of 2024.” Mr. Griffith continued: “In addition, NUC-7738, a ProTide transformation of a novel nucleoside analog, 3′-deoxyadenosine, is being assessed in the Phase 2 part of the ongoing Phase 1/2 NuTide:701 study in PD-1 inhibitor-resistant melanoma patients. Following a positive data update at the American Association for Cancer Research AACR Annual Meeting earlier this year, we plan to announce additional data at the upcoming European Society for Medical Oncology Congress 2024, being held September 13-17 in Barcelona, Spain.” Mr. Griffith concluded, “Our commitment to improving treatment outcomes for patients with cancer is what drives us to advance our development programs. We expect to announce numerous important data readouts in the second half of this year and look forward to providing updates on our progress.”